Learn More
7013 Background: In two Phase III trials (INTACT 1 & 2), gefitinib ('Iressa', ZD1839) in combination with first-line platinum-based chemotherapy regimens failed to show benefit in terms of survival(More)
INTRODUCTION Trials comparing the use of full dose unfractionated heparin (UFH) or low molecular weight heparins (LMWHs) in very elderly patients with impaired renal function are lacking. IRIS aimed(More)
PurposeTwo large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for(More)